Todd Nelson, Ph.D
Todd Nelson is the CEO of Codex. Over the past 20 years, he has had a distinguished career as an entrepreneur, life sciences executive, and investment banker.
In 2018, Todd joined on as CEO of SGI-DNA, which was at the time a subsidiary of Synthetic Genomics. Under his leadership, SGI-DNA spun out into an independent corporation in 2019 and secured a $25 Million Series A financing round to support the commercial launch of the BioXp™ 3200 system - the world's first and only fully automated gene synthesis and cloning platform. In 2020 SGI-DNA re-branded as Codex.
Todd has previously been the CEO of several life sciences companies through expansive phases of financial and commercial growth including eBioscience (acquired by Affymetrix, now Thermo Fisher Scientific), MP Biomedicals (acquired by Valeant Fine Chemicals), and most recently, DiscoverX Corporation (acquired by Eurofins). Todd is also the founder of Tonbo Biosciences and TCRx Corporation. Todd previously served as Vice President of Global Corporate Development at Life Technologies (now Thermo Fisher Scientific), and as Global Head of Life Sciences at RBC Capital Markets.
Todd received a Ph.D from the University of Minnesota in molecular pathology, and received advanced training as a senior fellow in clinical chemistry and molecular diagnostics at the Mayo Clinic. Todd received an MBA from the Carlson School of Business and his Bachelor’s degree from the University of Minnesota.